Skip to main content
12/18/2019

Latiglutenase for Celiac Disease Shows Symptom, Quality of Life Improvement

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…

Continue Reading
2/23/2015

Marilyn’s Message February 2015

I cannot stress enough how important your generous commitment is to our ongoing work here at Celiac Disease Foundation. I am pleased to report that we are making real progress in focusing resources and attention on celiac disease. For example, next month, the Food and Drug Administration (FDA) will be hosting a two-day meeting at…

Continue Reading